Cited by 600Ovarian cancer diagnosis and treatmentBRCA gene mutations in cancerPARP inhibition in cancer therapy

The DOI matches its Crossref record; 55 of the 58 references it cites were found in a registry or an index.

Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models

Open access

Perets, Ruth, Wyant, Gregory A., Muto, Katherine W., Bijron, Jonathan G., Poole, Barish B., Chin, Kenneth T., Chen, Jin Yun H., Ohman, Anders W., Stepule, Corey D., Kwak, Soongu, Karst, Alison M., Hirsch, Michelle S., Setlur, Sunita R., Crum, Christopher P., Dinulescu, Daniela M., Drapkin, Ronny·2013·Cancer Cell

DOI 10.1016/j.ccr.2013.10.013PMC PMC3917315

Open this paper in CoChat — free account Open PDF

Abstract

High-grade serous ovarian carcinoma presents significant clinical and therapeutic challenges. Although the traditional model of carcinogenesis has focused on the ovary as a tumor initiation site, recent studies suggest that there may be additional sites of origin outside the ovary, namely the secretory cells of the fallopian tube. Our study demonstrates that high-grade serous tumors can originate in fallopian tubal secretory epithelial cells and also establishes serous tubal intraepithelial carcinoma as the precursor lesion to high-grade serous ovarian and peritoneal carcinomas in animal models targeting the Brca, Tp53, and Pten genes. These findings offer an avenue to address clinically important questions that are critical for cancer prevention and early detection in women carrying BRCA1 and BRCA2 mutations.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2013.10.013

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Cancer statistics, 2012
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Generalized lacZ expression with the ROSA26 Cre reporter strain
Soriano, P. (1999) · Nature Genetics · doi:10.1038/5007 · Cited by 5,237
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I. G., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. P., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3144 · Cited by 1,484
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Alsop, K., Fereday, S., Meldrum, C. J., DeFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C. J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,204
Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship
Kindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C. M., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., et al. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213335.40358.47 · Cited by 1,114

Flagged first, then by citations

Show all 58 references

3 of the 58 references couldn’t be matched to a known paper.

Sorted by citations

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D. L., Böhm, S., Ahmed, A. A., Aspuria, P.-J. P., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S. P., Bookman, M. A., et al. (2015) · Nature reviews. Cancer · doi:10.1038/nrc4019 · Cited by 1,395
Ovarian cancer
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation
Chehelgerdi, M., Chehelgerdi, M., Allela, O. Q. B., Pecho, R. D. C., Narayanan, J., Rao, D. P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01865-0 · Cited by 1,132
The Dualistic Model of Ovarian Carcinogenesis
Kurman, R. J., & Shih, I. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.11.011 · Cited by 972
High grade serous ovarian carcinomas originate in the fallopian tube
Labidi‐Galy, S. I., Papp, E., Hallberg, D. L., Niknafs, N., Adleff, V., Noë, M., Bhattacharya, R., Novak, M., Jones, S., Phallen, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00962-1 · Cited by 762
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
Lisio, M. A., Fu, L., Goyeneche, A. A., Gao, Z., & Telleria, C. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040952 · Cited by 685
Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts
Eckert, M. A., Coscia, F., Chryplewicz, A., Chang, J. W., Hernandez, K. M., Pan, S., Tienda, S. M., Nahotko, D. A., Li, G., Blaženović, I., et al. (2019) · Nature · doi:10.1038/s41586-019-1173-8 · Cited by 503
The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids
Kessler, M., Hoffmann, K., Brinkmann, V., Thieck, O., Jackisch, S., Toelle, B., Berger, H., Mollenkopf, H., Mangler, M., Sehouli, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms9989 · Cited by 468
Coexistent ARID1A–PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling
Chandler, R. L., Damrauer, J. S., Raab, J. R., Schisler, J. C., Wilkerson, M. D., Didion, J. P., Starmer, J., Serber, D., Yee, D., Xiong, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms7118 · Cited by 327
Diagnosis and Treatment of Ovarian Cancer
Orr, B. C., & Edwards, R. P. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.07.010 · Cited by 322
Pathogenesis and heterogeneity of ovarian cancer
Kroeger, P., & Drapkin, R. (2016) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000340 · Cited by 322
The disparate origins of ovarian cancers: pathogenesis and prevention strategies
Karnezis, A. N., Cho, K. R., Gilks, C. B., Pearce, C. L., & Huntsman, D. D. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.113 · Cited by 303
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
Maxwell, K. N., Wubbenhorst, B., Wenz, B. M., De Sloover, D., Pluta, J., Emery, L., Barrett, A., Kraya, A. A., Anastopoulos, I. N., Yu, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00388-9 · Cited by 296
Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden
Stone, M. L., Chiappinelli, K. B., Li, H., Murphy, L. M., Travers, M. E., Topper, M. J., Mathios, D., Lim, M. K., Shih, I., Wang, T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712514114 · Cited by 297
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Worzfeld, T., von Strandmann, E. P., Huber, M., Adhikary, T., Wagner, U. A. G., Reinartz, S., & Müller, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00024 · Cited by 296
Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics
Prat, J., D′Angelo, E., & Espinosa, Í. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.06.018 · Cited by 283
Cell Origins of High-Grade Serous Ovarian Cancer
Kim, J., Park, E. Y., Kim, O., Schilder, J. M., Coffey, D., Cho, C., & Bast, R. C. (2018) · Cancers · doi:10.3390/cancers10110433 · Cited by 267
The Origin of Ovarian Cancer Species and Precancerous Landscape
Shih, I., Wang, Y., & Wang, T. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.09.006 · Cited by 265
The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance
Loret, N., Denys, H. G., Tummers, P., & Berx, G. (2019) · Cancers · doi:10.3390/cancers11060838 · Cited by 250
Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis
Wang, Y., Zhao, G., Condello, S., Huang, H., Cárdenas, H., Tanner, E. J., Wei, J., Ji, Y., Li, J., Tan, Y., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1488 · Cited by 246
CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma
Walton, J. B., Blagih, J., Ennis, D. P., Leung, E. Y. L., Dowson, S., Farquharson, M., Tookman, L. A., Orange, C., Athineos, D., Mason, S. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1272 · Cited by 236
Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma
Zhang, S., Dolgalev, I., Zhang, T., Ran, H., Levine, D. A., & Neel, B. G. (2019) · Nature Communications · doi:10.1038/s41467-019-13116-2 · Cited by 245
Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma
Ducie, J. A., Dao, F., Considine, M., Olvera, N., Shaw, P. A., Kurman, R. J., Shih, I., Soslow, R. A., Cope, L., & Levine, D. A. (2017) · Nature Communications · doi:10.1038/s41467-017-01217-9 · Cited by 227
Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube
Eckert, M. A., Pan, S., Hernandez, K. M., Loth, R. M., Andrade, J., Volchenboum, S. L., Faber, P. W., MONTAG, A. G., Lastra, R. R., Peter, M. E., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0607 · Cited by 212
The Repertoire of Serous Ovarian Cancer Non-genetic Heterogeneity Revealed by Single-Cell Sequencing of Normal Fallopian Tube Epithelial Cells
Hu, Z., Artibani, M., Alsaadi, A., Wietek, N. C., Morotti, M., Shi, T., Zhong, Z., González, L. S., El-Sahhar, S., Carrami, E. M., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.003 · Cited by 195
Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells
Testa, U., Petrucci, E., Pasquini, L., Castelli, G., & Pelosi, E. (2018) · Medicines · doi:10.3390/medicines5010016 · Cited by 196
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Kandalaft, L. E., Laniti, D. D., & Coukos, G. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00503-z · Cited by 190
TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer
Lecker, L. S. M., Berlato, C., Maniati, E., Delaine-Smith, R., Pearce, O. M. T., Heath, O. M., Nichols, S. J., Trevisan, C., Novak, M., McDermott, J. R., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0536 · Cited by 158
TP53 mutations in epithelial ovarian cancer
Zhang, Y., Cao, L., Nguyen, D., & Lu, H. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.08.40 · Cited by 156
Oxidative Phosphorylation: A Target for Novel Therapeutic Strategies Against Ovarian Cancer
Nayak, A. P., Kapur, A., Barroilhet, L. M., & Patankar, M. S. (2018) · Cancers · doi:10.3390/cancers10090337 · Cited by 149
Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer
Elias, K. M., Fendler, W. M., Stawiski, K., Fiascone, S. J., Vitonis, A. F., Berkowitz, R. S., Frendl, G., Konstantinopoulos, P. A., Crum, C. P., Kędzierska, M., et al. (2017) · eLife · doi:10.7554/elife.28932 · Cited by 142
Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention
Hanley, G. E., Pearce, C. L., Talhouk, A., Kwon, J. S., Finlayson, S. J., McAlpine, J. N., Huntsman, D. D., & Miller, D. M. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.47343 · Cited by 137
A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high‐grade serous carcinoma development
Sherman‐Baust, C. A., Kuhn, E., Valle, B. L., Shih, I., Kurman, R. J., Wang, T., Amano, T., Ko, M. S. H., Miyoshi, I., Araki, Y., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4353 · Cited by 136
Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy
Iyer, S., Zhang, S., Yucel, S., Horn, H., Smith, S. G., Reinhardt, F., Hoefsmit, E., Assatova, B., Casado, J., Meinsohn, M.-C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0818 · Cited by 136
RNA sequencing (RNA-Seq) and its application in ovarian cancer
Wang, J., Dean, D. C., Hornicek, F. J., Huirong, S., & Duan, Z. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.10.002 · Cited by 136
Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy
Park, Y., Chui, M. H., Rahmanto, Y. S., Yu, Z.-C., Shamanna, R. A., Bellani, M. A., Gaillard, S. L., Ayhan, A., Viswanathan, A., Seidman, M. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4222 · Cited by 138
Complement Pathway Is Frequently Altered in Endometriosis and Endometriosis-Associated Ovarian Cancer
Suryawanshi, S., Huang, X., Elishaev, E., Budiu, R. A., Zhang, L., Kim, S., Donnellan, N. M., Mantia-Smaldone, G. M., Ma, T., Tseng, G. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1338 · Cited by 130
ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion
Wilson, M. R., Reske, J. J., Holladay, J., Moldovan, G. E., Rhodes, M., Koeman, J. M., Adams, M., Johnson, B. K., Su, R., Joshi, N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11403-6 · Cited by 127
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer
Saux, O. L., Ray-Coquard, I. L., & Labidi‐Galy, S. I. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.017 · Cited by 127
Hippo Signaling in the Ovary: Emerging Roles in Development, Fertility, and Disease
Clark, K. L., George, J. W., Przygrodzka, E., Plewes, M. R., Hua, G., Wang, C., & Davis, J. S. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac013 · Cited by 129
Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids
Lõhmussaar, K., Kopper, O., Korving, J., Begthel, H., Vreuls, C. P. H., van Es, J. H., & Clevers, H. C. (2020) · Nature Communications · doi:10.1038/s41467-020-16432-0 · Cited by 126
Diagnosis of ovarian cancer
Sundar, S. S., Neal, R. D., & Kehoe, S. T. (2015) · BMJ · doi:10.1136/bmj.h4443 · Cited by 120
Screening for ovarian cancer: imaging challenges and opportunities for improvement
Mathieu, K. B., Bedi, D. G., Thrower, S. L., Qayyum, A., & Bast, R. C. (2017) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.17557 · Cited by 118
Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
Taylor‐Harding, B., Aspuria, P.-J. P., Agadjanian, H., Cheon, D., Mizuno, T., Greenberg, D. N., Allen, J. R., Spurka, L., Funari, V. A., Spiteri, E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2673 · Cited by 117
It's Totally Tubular…Riding The New Wave of Ovarian Cancer Research
Perets, R., & Drapkin, R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1382 · Cited by 116
Functional neuronal circuits promote disease progression in cancer
Kovacs, A., Vermeer, D. W., Madeo, M., Reavis, H. D., Vermeer, S. J., Williamson, C. S., Rickel, A. P., Stamp, J., Lucido, C. T., Cain, J. T., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade4443 · Cited by 119
Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment
Maniati, E., Berlato, C., Gopinathan, G., Heath, O. M., Kotantaki, P., Lakhani, A., McDermott, J. R., Pegrum, C., Delaine‐Smith, R. M., Pearce, O. M. T., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.12.034 · Cited by 110
Evidence for a Dualistic Model of High-grade Serous Carcinoma
Howitt, B. E., Hanamornroongruang, S., Lin, D. I., Conner, J. E., Schulte, S., Horowitz, N. S., Crum, C. P., & Meserve, E. E. K. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000369 · Cited by 111
Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
Drakes, M. L., & Stiff, P. J. (2018) · Cancers · doi:10.3390/cancers10090302 · Cited by 115
Single-cell transcriptomics identifies gene expression networks driving differentiation and tumorigenesis in the human fallopian tube
Dinh, H. Q., Lin, X., Abbasi, F., Nameki, R. A., Haro, M., Olingy, C. E., Chang, H. S. Y., Hernández, L., Gayther, S. A., Wright, K. N., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108978 · Cited by 110
CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity
Walton, J. B., Farquharson, M., Mason, S. M., Port, J., Kruspig, B., Dowson, S., Stevenson, D., Murphy, D. J., Matzuk, M. M., Kim, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17119-1 · Cited by 110
A Microfluidic Chip Enables Isolation of Exosomes and Establishment of Their Protein Profiles and Associated Signaling Pathways in Ovarian Cancer
Dorayappan, K. D. P., Gardner, M. L., Hisey, C. L., Zingarelli, R. A., Smith, B. Q., Lightfoot, M. D. S., Gogna, R., Flannery, M. M., Hays, J. L., Hansford, D. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3538 · Cited by 109
Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier
Martins, F. C., de Santiago, I., Trinh, A. C., Xian, J., Guo, A., Sayal, K., Jimenez‐Liñan, M., Deen, S., Driver, K. E., Mack, M. L., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0526-8 · Cited by 108
Genetic and molecular changes in ovarian cancer
Hollis, R. L., Hollis, R. L., Gourley, C., & Gourley, C. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0024 · Cited by 107
Tumor–Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure
von Strandmann, E. P., Reinartz, S., Wager, U., & Müller, R. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.12.005 · Cited by 102
Stromal expression of fibroblast activation protein alpha (fap) predicts platinum resistance and shorter recurrence in patients with epithelial ovarian cancer
Mhawech-Fauceglia, P., Yan, L., Sharifian, M., Ren, X., Liu, S., Kim, G., Gayther, S. A., Pejovic, T., & Lawrenson, K. (2015) · Cancer Microenvironment · doi:10.1007/s12307-014-0153-7 · Cited by 95
miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma
Dong, R., Liu, X., Zhang, Q., Jiang, Z., Li, Y., Wei, Y., Li, Y., Yang, Q., Liu, J., Wei, J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2522 · Cited by 100
FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer
Liu, C., Barger, C. J., & Karpf, A. R. (2021) · Cancers · doi:10.3390/cancers13123065 · Cited by 99
Deciphering the BRCA1 Tumor Suppressor Network
Jiang, Q., & Greenberg, R. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.667931 · Cited by 96
High‐grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease
Zhai, Y., WU, R. T., Kuick, R. D., Sessine, M. S., Schulman, S., Green, M., Fearon, E. R., & Cho, K. R. (2017) · The Journal of Pathology · doi:10.1002/path.4927 · Cited by 95
A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity
Nelson, L., Tighe, A., Golder, A., Littler, S., Bakker, B., Moralli, D., Baker, S. M., Donaldson, I. J., Spierings, D. C. J., Wardenaar, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14551-2 · Cited by 97
Palladium(II)‐η3‐Allyl Complexes Bearing N‐Trifluoromethyl N‐Heterocyclic Carbenes: A New Generation of Anticancer Agents that Restrain the Growth of High‐Grade Serous Ovarian Cancer Tumoroids
Scattolin, T., Bortolamiol, E., Visentin, F., Palazzolo, S., Caligiuri, I., Perin, T., Canzonieri, V., Demitri, N., Rizzolio, F., & Togni, A. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202002199 · Cited by 95
Organoids of the female reproductive tract
Chumduri, C., & Turco, M. Y. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02028-0 · Cited by 110
Serous tubal intraepithelial neoplasia: the concept and its application
Meserve, E. E. K., Brouwer, J., & Crum, C. P. (2017) · Modern Pathology · doi:10.1038/modpathol.2016.238 · Cited by 94
The activity of tertiary lymphoid structures in high grade serous ovarian cancer is governed by site, stroma, and cellular interactions
MacFawn, I., Magnon, G. C., Gorecki, G., Kunning, S. R., Rashid, R., Ernest, M., Atiya, H. I., Ruffin, A. T., Taylor, S., Soong, T. R., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.007 · Cited by 98
PRKCI promotes immune suppression in ovarian cancer
Sarkar, S., Bristow, C. A., Dey, P., Rai, K., Perets, R., Ramirez-Cardenas, A., Malasi, S., Huang-Hobbs, E., Haemmerle, M., Wu, S. Y., et al. (2017) · Genes & Development · doi:10.1101/gad.296640.117 · Cited by 93
Self-citation
Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming
Rahmanto, Y. S., Shen, W., Shi, X., Chen, X. X., Yu, Y., Yu, Z.-C., Miyamoto, T., Lee, M.-H., Singh, V., Asaka, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16416-0 · Cited by 91
Chlamydia infection depends on a functional MDM2-p53 axis
González, E., Rother, M., Kerr, M. C., Al‐Zeer, M. A., Lubad, M. A., Kessler, M., Brinkmann, V., Loewer, A., & Meyer, T. F. (2014) · Nature Communications · doi:10.1038/ncomms6201 · Cited by 93
In vivo genetic cell lineage tracing reveals that oviductal secretory cells self-renew and give rise to ciliated cells
Ghosh, A., Syed, S. M., & Tanwar, P. S. (2017) · Development · doi:10.1242/dev.149989 · Cited by 92
Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer
Zhang, S., Iyer, S., Ran, H., Dolgalev, I., Gu, S. S., Wei, W., Foster, C., Loomis, C. A., Olvera, N., Dao, F., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0455 · Cited by 89
Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer
Paffenholz, S. V., Salvagno, C., Ho, Y.-J., Limjoco, M., Baslan, T., Tian, S., Kulick, A. R., de Stanchina, E., Wilkinson, J. E., Barriga, F. M., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2117754119 · Cited by 93
Ovary and fimbrial stem cells: biology, niche and cancer origins
Ng, A., & Barker, N. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4056 · Cited by 94
Mutagenic, surviving and tumorigenic effects of follicular fluid in the context of p53 loss: initiation of fimbria carcinogenesis
Huang, H.-S., Chu, S., Hsu, C., Chen, P., Ding, D., Chang, M.-Y., & Chu, T. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv132 · Cited by 89
CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma
Kuhn, E., Wang, T., Doberstein, K., Bahadirli-Talbott, A., Ayhan, A., Sehdev, A. E. S., Drapkin, R., Kurman, R. J., & Shih, I. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.101 · Cited by 87
High-throughput approaches for precision medicine in high-grade serous ovarian cancer
Govindarajan, M., Wohlmuth, C., Waas, M., Bernardini, M. Q., & Kislinger, T. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00971-6 · Cited by 89
New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination
Coffman, L. G., Burgos-Ojeda, D., WU, R. T., Cho, K. R., Bai, S., & Buckanovich, R. J. (2016) · Translational research · doi:10.1016/j.trsl.2016.03.016 · Cited by 87
YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells
Hua, G., Lv, X., He, C., Remmenga, S. W., Rodabough, K. J., Dong, J., Yang, L., Lele, S. M., Yang, P., Zhou, J., et al. (2015) · Oncogene · doi:10.1038/onc.2015.288 · Cited by 83
Long-term organoid culture reveals enrichment of organoid-forming epithelial cells in the fimbrial portion of mouse fallopian tube
Xie, Y., Park, E., Xiang, D., & Li, Z. (2018) · Stem Cell Research · doi:10.1016/j.scr.2018.08.021 · Cited by 78
TGFβ signaling networks in ovarian cancer progression and plasticity
Kumari, A., Shonibare, Z., Monavarian, M., Arend, R. C., Lee, N. Y., Inman, G. J., & Mythreye, K. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10077-z · Cited by 78
Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer
Muñoz-Galván, S., & Carnero, A. (2020) · Cells · doi:10.3390/cells9061402 · Cited by 81
Activin A stimulates migration of the fallopian tube epithelium, an origin of high-grade serous ovarian cancer, through non-canonical signaling
Dean, M., Davis, D. A., & Burdette, J. E. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.011 · Cited by 80
Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention
George, S. H. L., Garcia, R., & Slomovitz, B. M. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00108 · Cited by 82
Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy
Xu, B., Lefringhouse, J., Liu, Z., Piecoro, D. W., Baldwin, L. A., Ou, C., Chen, L., Napier, D. L., Chaiswing, L., Brewer, L. D., et al. (2017) · Oncogenesis · doi:10.1038/oncsis.2016.86 · Cited by 76
The Ovary Is an Alternative Site of Origin for High-Grade Serous Ovarian Cancer in Mice
Kim, J., Coffey, D. M., Ma, L., & Matzuk, M. M. (2015) · Endocrinology · doi:10.1210/en.2014-1977 · Cited by 76
Directed Differentiation of Human Induced Pluripotent Stem Cells into Fallopian Tube Epithelium
Yucer, N., Holzapfel, M., Vogel, T. J., Lenaeus, L., Ornelas, L., Laury, A. R., Sareen, D., Barrett, R. J., Karlan, B. Y., & Svendsen, C. N. (2017) · Scientific Reports · doi:10.1038/s41598-017-05519-2 · Cited by 75
Dissecting metastasis using preclinical models and methods
Hebert, J. D., Neal, J. W., & Winslow, M. M. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00568-4 · Cited by 78
In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells
Yamamoto, Y., Ning, G., Howitt, B. E., Mehra, K. K., Wu, L., Wang, X., Yue, H., Kern, F., Wei, T. S., Zhang, T., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4649 · Cited by 75
Impact of oviductal versus ovarian epithelial cell of origin on ovarian endometrioid carcinoma phenotype in the mouse
WU, R. T., Zhai, Y., Kuick, R. D., Karnezis, A. N., Garcia, P. E., Naseem, A. F., Hu, T. C., Fearon, E. R., & Cho, K. R. (2016) · The Journal of Pathology · doi:10.1002/path.4783 · Cited by 75
Overexpression of CD47 predicts poor prognosis and promotes cancer cell invasion in high-grade serous ovarian carcinoma.
Li, Y., Lu, S., Xu, Y., Qiu, C., Jin, C., Wang, Y., Liu, Z., & Kong, B. (2017) · PubMed Central · Cited by 74
Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer
Harrington, B. S., He, Y., Davies, C. M., Wallace, S. J., Adams, M. N., Beaven, E. A., Roche, D., Kennedy, C. J., Chetty, N., Crandon, A. J., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.471 · Cited by 73
Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution
Bartlett, T. E., Chindera, K., McDermott, J. R., Breeze, C. E., Cooke, W. R., Jones, A., Reisel, D., Karegodar, S. T., Arora, R., Beck, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms11620 · Cited by 72
Molecular and cellular mechanisms controlling integrin-mediated cell adhesion and tumor progression in ovarian cancer metastasis: a review
Dhaliwal, D., & Shepherd, T. G. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10136-5 · Cited by 71
Salpingectomy as a Means to Reduce Ovarian Cancer Risk
Daly, M. B., Drescher, C. W., Yates, M. S., Jeter, J., Karlan, B. Y., Alberts, D. S., & Lu, K. H. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0293 · Cited by 71
PAX8 and MECOM are interaction partners driving ovarian cancer
Bleu, M., Mermet‐Meillon, F., Apfel, V., Barys, L., Holzer, L., Salvy, M. B., Lopes, R., Barbosa, I. A. M., Delmas, C., Hinniger, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22708-w · Cited by 69
Can Stemness and Chemoresistance Be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer?
Roy, L., & Dahl, K. D. C. (2018) · Cancers · doi:10.3390/cancers10080241 · Cited by 69
PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation
Russo, A., Czarnecki, A. A., Dean, M., Modi, D., Lantvit, D. D., Hardy, L. R., Baligod, S., Davis, D. A., Wei, J., & Burdette, J. E. (2018) · Oncogene · doi:10.1038/s41388-017-0097-8 · Cited by 69
PAX8 activates metabolic genes via enhancer elements in Renal Cell Carcinoma
Bleu, M., Gaulis, S., Lopes, R., Sprouffske, K., Apfel, V., Holwerda, S. J. B., Pregnolato, M., Yildiz, U., Cordo’, V., Dost, A. F. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11672-1 · Cited by 69
Chemotherapy Induces Tumor-Associated Macrophages that Aid Adaptive Immune Responses in Ovarian Cancer
Heath, O. M., Berlato, C., Maniati, E., Lakhani, A., Pegrum, C., Kotantaki, P., Elorbany, S., Böhm, S., Barry, S. T., Annibaldi, A., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0968 · Cited by 69
Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods
Ahmed, N., Kadife, E., Raza, A., Short, M. K., Jubinsky, P. T., & Kannourakis, G. (2020) · Cells · doi:10.3390/cells9030719 · Cited by 69
Biology-driven therapy advances in high-grade serous ovarian cancer
Wang, Y., Duval, A. J., Adli, M., & Matei, D. E. (2024) · Journal of Clinical Investigation · doi:10.1172/jci174013 · Cited by 74

Authors: Perets, R., Wyant, G. A., Muto, K. W., Bijron, J. G., Poole, B. B., Chin, K. T., Chen, J. Y. H., Ohman, A. W., Stepule, C. D., Kwak, S., Karst, A. M., Hirsch, M. S., Setlur, S. R., Crum, C. P., Dinulescu, D. M., & Drapkin, R.
Affiliations: Harvard University (US)
Brigham and Women's Hospital (US)
Corresponding author: Dinulescu, Daniela M.
Drapkin, Ronny
ORCID: Perets, Ruth
Wyant, Gregory A.
Hirsch, Michelle S.
Setlur, Sunita R.
Crum, Christopher P.
Dinulescu, Daniela M.
Drapkin, Ronny
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2013-12
Volume: 24
Issue: 6
Pages: 751-765
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2013.10.013
PMC: PMC3917315
OpenAlex: W2013107316
Cited by: 596
References: 58
Citations by year: 2026: 23 · 2025: 49 · 2024: 35 · 2023: 47 · 2022: 47 · 2021: 46 · 2020: 85 · 2019: 44 · 2018: 42 · 2017: 44 · 2016: 51 · 2015: 49 · 2014: 32
FWCI: 52.89
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 373 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Wellcome Trust
National Institutes of Health
National Cancer Institute (R21CA156021, U01CA152990, P50CA105009)
Topics: Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords: high-grade serous ovarian cancer, serous tubal intraepithelial carcinoma, cancer of unknown primary, BRCA1, BRCA2, TP53, PTEN, peritoneal cancer, precursor lesions, cancer prevention, early detection
MeSH terms: PAX8 Transcription Factor, Animals, Cell Transformation, Neoplastic, Epithelium, Fallopian Tube Neoplasms, Female, Mice, Inbred C57BL, Ovarian Neoplasms, Precancerous Conditions, Genes, p53, Cystadenocarcinoma, Serous, Genes, BRCA1, Integrases, Genes, BRCA2, PTEN Phosphohydrolase, Mice, Paired Box Transcription Factors, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks